Generative search and social discovery are amplifying this divide. As AI systems personalize results based on user context, interests, and engagement patterns, the internet is effectively splitting ...

In Canada, the patent for some semaglutide drugs has expired, paving the way for the country to become the first to offer ...

Danish drug maker Novo Nordisk is preparing to introduce a new version of its blockbuster drug Ozempic to compete with ...

Drug companies in Canada are allowed to make lower priced generic versions of the blockbuster drug Ozempic as of next week, ...

Qatar Airways, Singapore Airlines, ANA, Cathay Pacific, and Air France rank among the strongest business class products.

We’ve entered a new era of creative expression, where anyone with an internet connection can generate images and videos from text descriptions. But there’s a frustrating gap between using AI ...

U.S. drugmaker Lilly's Mounjaro, approved for diabetes and weight loss in India, became the top-selling therapy by value in October, with sales doubling within months of its March launch, outpacing ...

Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...